Last reviewed · How we verify

NCT05107791

Effects of Stulln and Accommodative Training

Withdrawn Phase 1, PHASE2 Last updated 21 May 2024
What this trial tests

Phase 1, PHASE2 trial testing Stulln Eyedrops in Accommodation Disorder. Withdrawn.

Timeline
15 March 2021
Primary endpoint
31 August 2021
31 August 2021

Quick facts

Lead sponsorPacific University
PhasePhase 1, PHASE2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Start date15 March 2021
Primary completion31 August 2021
Estimated completion31 August 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Pacific University

Who can join

Adults 18 to 35, any sex, with Accommodation Disorder or Visual Fatigue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study tests the hypothesis that Stulln eyedrops improve accommodative functions by improving the short term facility of ciliary muscles that can be transferred into long-term adaptation. To test this, the investigators propose to conduct a prospective randomized control trials where participants with accommodative dysfunctions are randomly assigned to four groups: control, Stulln only and Stulln plus vision training. The investigators' theory predicts that the efficacy of Stulln will be augmented by vision training.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Pacific University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05107791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing